

ANTARES PHARMA INC  
Form 8-A12B  
September 22, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES**  
**PURSUANT TO SECTION 12(b) OR (g) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

---

**ANTARES PHARMA, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Minnesota**  
(State of Incorporation  
or Organization)

**41-1350192**  
(I.R.S. Employer  
Identification No.)

**707 Eagleview Boulevard, Suite 414**

**Exton, PA 19341**

(Address of Principal Executive Offices)

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A. (c), check the following box.

Edgar Filing: ANTARES PHARMA INC - Form 8-A12B

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A. (d), check the following box. "

Securities Act registration statement file number to which this form relates: [Not Applicable]

Securities to be registered pursuant to Section 12(b) of the Act:

**Title of Each Class**

**Name of Each Exchange On Which**

**To Be So Registered**

**Each Class Is To Be Registered**

Common Stock, par value \$.01 per share

American Stock Exchange

---

**Item 1. Description of Registrant's Securities to be Registered.**

The Registrant incorporates by reference the description of its common stock included in the Registrant's Registration Statement on Form S-1/A (Registration No. 333-6661), filed with the Securities and Exchange Commission on August 15, 1996, including any amendment or report filed for the purpose of updating such description.

**Item 2. Exhibits.**

None.

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Date: September 22, 2004

Antares Pharma, Inc.

By: /s/ Jack Stover  
Jack Stover  
Chief Executive Officer